Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
In the 28-week, phase three randomized control trial (RCT) DURATION-8, dual therapy with an SGLT2 inhibitor (dapagliflozin) and a GLP-1RA (once-weekly exenatide) was shown to reduce HbA1c by 0.4% more than either agent alone, in patients with a starting HbA1c of between 8-12% 50 , illustrating that the glycemic response to dual therapy is less than additive 50
C., Cooper-Cox, K
It should not be combined with other semaglutide or GLP-1 products
doi:10.1074/jbc.M209264200 43
Will I need to change my diet or exercise habits
(PubMed) American Academy of Pediatrics, Committee on Nutrition
US$ 25.67
US$ 21.14
US$ 26.87
US$ 28.87
US$ 27.24
US$ 29.51
.png)
US$ 21.69
US$ 20.77
US$ 28.35
US$ 25.64
![COMICS [3] COLORS SINGLE STICKERS](https://cdn.shopify.com/s/files/1/0852/5253/8682/files/COMICS_3.webp?v=1703636549)
